A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting

Phase 2

DAP & TOM, BepirovirsenA Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Sponsor:

GlaxoSmithKline

Code:

NCT06537414

Conditions

Chronic Hepatitis B Virus Infection

Hepatitis B

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Daplusiran/Tomligisiran Dose Level 1

Daplusiran/Tomligisiran Dose Level 2

Bepirovirsen

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-25. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2025-05-18.